View More Recent Stories

Jun 1, 2022 04:05PM Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Jun 1, 2022 07:01AM Apellis Pharmaceuticals (APLS) Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
Jun 1, 2022 07:00AM Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
Jun 1, 2022 07:00AM Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
May 12, 2022 11:05AM Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
May 12, 2022 11:05AM Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
May 6, 2022 04:23PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2022 04:23PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2022 04:05PM Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
May 4, 2022 04:05PM Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
May 3, 2022 07:00AM Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company
May 3, 2022 07:00AM Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company
May 2, 2022 03:32PM Apellis Pharmaceuticals (APLS) Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy at ARVO Annual Meeting
May 2, 2022 03:30PM Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
May 2, 2022 03:30PM Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
Apr 26, 2022 07:00AM Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results
Apr 26, 2022 07:00AM Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results
Apr 21, 2022 07:00AM Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)
Apr 21, 2022 07:00AM Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)
Apr 4, 2022 07:00AM Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
Apr 4, 2022 07:00AM Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
Mar 16, 2022 07:00AM Apellis Pharmaceuticals (APLS) Reports Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
Mar 16, 2022 07:00AM Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
Mar 16, 2022 07:00AM Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
Jul 6, 2021 08:00AM Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board
Apr 17, 2018 09:22AM Pre-Open Movers 04/17: (RNDA) (ROKU) (NFLX) Higher; (BLCM) (LADR) (SEAC) Lower (more...)
Dec 13, 2017 10:00AM Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) to Ring The Nasdaq Stock Market Closing Bell
View More Recent Stories